PDCD1 and neoplasm: The underlying mechanism of action of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of advanced UC could be the fact that PD-1/PD-L1 antibodies prevents the immune escape of tumor cells by blocking the binding of PD-1 on T cells to its ligand on tumor cells.